Nectar Lifesciences Limited (BOM:532649)

Market Cap	2.06B -36.5%
Revenue (ttm)	145.00K -100.0%
Net Income	-2.45B
EPS	-11.60
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,281
Open	10.66
Previous Close	11.03
Day's Range	10.53 - 10.95
52-Week Range	9.20 - 22.49
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Nectar Lifesciences

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufa...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 111
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532649

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 7, 2026

Data Sources Report a data error